An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer (HRPC) and Rising Prostate Specific Antigen (PSA) Levels Who Have Not Received Prior Chemotherapy
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of participants with adverse events.
Lance Leopold, MD
Ascenta Therapeutics, Inc.
United States: Food and Drug Administration
|New Britain, Connecticut 06052|
|Fountain Valley, California 92708|
|Nashville, Tennessee 37203-1632|